Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure)

Alessandro Boccanelli, Giuseppe Cacciatore, Gian Francesco Mureddu, Giovanni De Simone, Francesco Clemenza, Renata De Maria, Andrea Di Lenarda, Antonello Gavazzi, Roberto Latini, Serge Masson, Maurizio Porcu, Massimo Vanasia, Lucio Gonzini, Aldo Pietro Maggioni

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Excess aldosterone activity contributes to the pathogenesis and progression of heart failure (HF). Aldosterone antagonists improve clinical outcome in patients with severe HF or left ventricular (LV) dysfunction after myocardial infarction, but knowledge of their impact in mild chronic HF is sparse. AREA IN-CHF was planned to investigate the effects of canrenone on progression of LV remodelling in mild HF. METHODS: AREA IN-CHF is a multicentre, randomised, double-blind, parallel group comparison of canrenone (up to 50 mg/day) versus placebo in mild stable HF. The primary endpoint is change in echocardiographic LV end-diastolic volume over 12 months. Patients had New York Heart Association class II HF, LV ejection fraction ≤45%, stable standard therapy, creatinine ≤2.5 mg/dl, potassium ≤5.0 mmol/l. Follow-up examinations were scheduled monthly for the first 3 months and every 3 months thereafter. Aldosterone was measured at baseline, brain natriuretic peptide and procollagen type III amino-terminal peptide (PIIINP) at baseline and at 6 months. Echocardiography was performed at baseline, at 6 and 12 months. RESULTS: Among 467 patients, median age 64 years (interquartile range (IQR) 56-70 years), 84% were men, 52% had ischaemic HF, 96% were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, 79% β-blockers. Brain natriuretic peptide, aldosterone and PIIINP were 88 pg/ml (IQR 35-185 pg/ml), 118 pg/ml (IQR 75-177 pg/ml), and 5.38 μg/l (IQR 3.98-7.14 μg/l), respectively. LV end-diastolic volume was 79 ml/m (IQR 64-105 ml/m) and LV ejection fraction was 40% (IQR 33-45%). CONCLUSIONS: The role of aldosterone blockade in patients with mild HF remains to be established. AREA IN-CHF is addressing this issue in a large population on optimal medical therapy.

Original languageEnglish
Pages (from-to)683-691
Number of pages9
JournalJournal of Cardiovascular Medicine
Volume8
Issue number9
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Canrenone
Mineralocorticoid Receptors
Heart Failure
Aldosterone
Stroke Volume
Brain Natriuretic Peptide
Mineralocorticoid Receptor Antagonists
Ventricular Remodeling
Angiotensin Receptor Antagonists
Left Ventricular Dysfunction
Angiotensin-Converting Enzyme Inhibitors
Echocardiography
Creatinine
Potassium
Myocardial Infarction
Placebos

Keywords

  • Aldosterone blockade
  • Canrenone
  • Cardiac remodelling
  • Heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). / Boccanelli, Alessandro; Cacciatore, Giuseppe; Mureddu, Gian Francesco; De Simone, Giovanni; Clemenza, Francesco; De Maria, Renata; Di Lenarda, Andrea; Gavazzi, Antonello; Latini, Roberto; Masson, Serge; Porcu, Maurizio; Vanasia, Massimo; Gonzini, Lucio; Maggioni, Aldo Pietro.

In: Journal of Cardiovascular Medicine, Vol. 8, No. 9, 09.2007, p. 683-691.

Research output: Contribution to journalArticle

Boccanelli, A, Cacciatore, G, Mureddu, GF, De Simone, G, Clemenza, F, De Maria, R, Di Lenarda, A, Gavazzi, A, Latini, R, Masson, S, Porcu, M, Vanasia, M, Gonzini, L & Maggioni, AP 2007, 'Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure)', Journal of Cardiovascular Medicine, vol. 8, no. 9, pp. 683-691. https://doi.org/10.2459/JCM.0b013e3281053a9a
Boccanelli, Alessandro ; Cacciatore, Giuseppe ; Mureddu, Gian Francesco ; De Simone, Giovanni ; Clemenza, Francesco ; De Maria, Renata ; Di Lenarda, Andrea ; Gavazzi, Antonello ; Latini, Roberto ; Masson, Serge ; Porcu, Maurizio ; Vanasia, Massimo ; Gonzini, Lucio ; Maggioni, Aldo Pietro. / Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). In: Journal of Cardiovascular Medicine. 2007 ; Vol. 8, No. 9. pp. 683-691.
@article{92be59be6ff54a92b189d916374aa139,
title = "Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure)",
abstract = "OBJECTIVE: Excess aldosterone activity contributes to the pathogenesis and progression of heart failure (HF). Aldosterone antagonists improve clinical outcome in patients with severe HF or left ventricular (LV) dysfunction after myocardial infarction, but knowledge of their impact in mild chronic HF is sparse. AREA IN-CHF was planned to investigate the effects of canrenone on progression of LV remodelling in mild HF. METHODS: AREA IN-CHF is a multicentre, randomised, double-blind, parallel group comparison of canrenone (up to 50 mg/day) versus placebo in mild stable HF. The primary endpoint is change in echocardiographic LV end-diastolic volume over 12 months. Patients had New York Heart Association class II HF, LV ejection fraction ≤45{\%}, stable standard therapy, creatinine ≤2.5 mg/dl, potassium ≤5.0 mmol/l. Follow-up examinations were scheduled monthly for the first 3 months and every 3 months thereafter. Aldosterone was measured at baseline, brain natriuretic peptide and procollagen type III amino-terminal peptide (PIIINP) at baseline and at 6 months. Echocardiography was performed at baseline, at 6 and 12 months. RESULTS: Among 467 patients, median age 64 years (interquartile range (IQR) 56-70 years), 84{\%} were men, 52{\%} had ischaemic HF, 96{\%} were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, 79{\%} β-blockers. Brain natriuretic peptide, aldosterone and PIIINP were 88 pg/ml (IQR 35-185 pg/ml), 118 pg/ml (IQR 75-177 pg/ml), and 5.38 μg/l (IQR 3.98-7.14 μg/l), respectively. LV end-diastolic volume was 79 ml/m (IQR 64-105 ml/m) and LV ejection fraction was 40{\%} (IQR 33-45{\%}). CONCLUSIONS: The role of aldosterone blockade in patients with mild HF remains to be established. AREA IN-CHF is addressing this issue in a large population on optimal medical therapy.",
keywords = "Aldosterone blockade, Canrenone, Cardiac remodelling, Heart failure",
author = "Alessandro Boccanelli and Giuseppe Cacciatore and Mureddu, {Gian Francesco} and {De Simone}, Giovanni and Francesco Clemenza and {De Maria}, Renata and {Di Lenarda}, Andrea and Antonello Gavazzi and Roberto Latini and Serge Masson and Maurizio Porcu and Massimo Vanasia and Lucio Gonzini and Maggioni, {Aldo Pietro}",
year = "2007",
month = "9",
doi = "10.2459/JCM.0b013e3281053a9a",
language = "English",
volume = "8",
pages = "683--691",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure)

AU - Boccanelli, Alessandro

AU - Cacciatore, Giuseppe

AU - Mureddu, Gian Francesco

AU - De Simone, Giovanni

AU - Clemenza, Francesco

AU - De Maria, Renata

AU - Di Lenarda, Andrea

AU - Gavazzi, Antonello

AU - Latini, Roberto

AU - Masson, Serge

AU - Porcu, Maurizio

AU - Vanasia, Massimo

AU - Gonzini, Lucio

AU - Maggioni, Aldo Pietro

PY - 2007/9

Y1 - 2007/9

N2 - OBJECTIVE: Excess aldosterone activity contributes to the pathogenesis and progression of heart failure (HF). Aldosterone antagonists improve clinical outcome in patients with severe HF or left ventricular (LV) dysfunction after myocardial infarction, but knowledge of their impact in mild chronic HF is sparse. AREA IN-CHF was planned to investigate the effects of canrenone on progression of LV remodelling in mild HF. METHODS: AREA IN-CHF is a multicentre, randomised, double-blind, parallel group comparison of canrenone (up to 50 mg/day) versus placebo in mild stable HF. The primary endpoint is change in echocardiographic LV end-diastolic volume over 12 months. Patients had New York Heart Association class II HF, LV ejection fraction ≤45%, stable standard therapy, creatinine ≤2.5 mg/dl, potassium ≤5.0 mmol/l. Follow-up examinations were scheduled monthly for the first 3 months and every 3 months thereafter. Aldosterone was measured at baseline, brain natriuretic peptide and procollagen type III amino-terminal peptide (PIIINP) at baseline and at 6 months. Echocardiography was performed at baseline, at 6 and 12 months. RESULTS: Among 467 patients, median age 64 years (interquartile range (IQR) 56-70 years), 84% were men, 52% had ischaemic HF, 96% were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, 79% β-blockers. Brain natriuretic peptide, aldosterone and PIIINP were 88 pg/ml (IQR 35-185 pg/ml), 118 pg/ml (IQR 75-177 pg/ml), and 5.38 μg/l (IQR 3.98-7.14 μg/l), respectively. LV end-diastolic volume was 79 ml/m (IQR 64-105 ml/m) and LV ejection fraction was 40% (IQR 33-45%). CONCLUSIONS: The role of aldosterone blockade in patients with mild HF remains to be established. AREA IN-CHF is addressing this issue in a large population on optimal medical therapy.

AB - OBJECTIVE: Excess aldosterone activity contributes to the pathogenesis and progression of heart failure (HF). Aldosterone antagonists improve clinical outcome in patients with severe HF or left ventricular (LV) dysfunction after myocardial infarction, but knowledge of their impact in mild chronic HF is sparse. AREA IN-CHF was planned to investigate the effects of canrenone on progression of LV remodelling in mild HF. METHODS: AREA IN-CHF is a multicentre, randomised, double-blind, parallel group comparison of canrenone (up to 50 mg/day) versus placebo in mild stable HF. The primary endpoint is change in echocardiographic LV end-diastolic volume over 12 months. Patients had New York Heart Association class II HF, LV ejection fraction ≤45%, stable standard therapy, creatinine ≤2.5 mg/dl, potassium ≤5.0 mmol/l. Follow-up examinations were scheduled monthly for the first 3 months and every 3 months thereafter. Aldosterone was measured at baseline, brain natriuretic peptide and procollagen type III amino-terminal peptide (PIIINP) at baseline and at 6 months. Echocardiography was performed at baseline, at 6 and 12 months. RESULTS: Among 467 patients, median age 64 years (interquartile range (IQR) 56-70 years), 84% were men, 52% had ischaemic HF, 96% were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, 79% β-blockers. Brain natriuretic peptide, aldosterone and PIIINP were 88 pg/ml (IQR 35-185 pg/ml), 118 pg/ml (IQR 75-177 pg/ml), and 5.38 μg/l (IQR 3.98-7.14 μg/l), respectively. LV end-diastolic volume was 79 ml/m (IQR 64-105 ml/m) and LV ejection fraction was 40% (IQR 33-45%). CONCLUSIONS: The role of aldosterone blockade in patients with mild HF remains to be established. AREA IN-CHF is addressing this issue in a large population on optimal medical therapy.

KW - Aldosterone blockade

KW - Canrenone

KW - Cardiac remodelling

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=34548040240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548040240&partnerID=8YFLogxK

U2 - 10.2459/JCM.0b013e3281053a9a

DO - 10.2459/JCM.0b013e3281053a9a

M3 - Article

C2 - 17700397

AN - SCOPUS:34548040240

VL - 8

SP - 683

EP - 691

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 9

ER -